ResMed Inc. RMD
222.00
0.11
0.05%
as of 25 Sep
- Market cap
- $31.9B
- P/E
- 21.3×
Follow RMD
Indexes
indicate stock being part of an index,
Growth Flags
show if company had growth for consecutive years
ResMed Inc. (RMD) Gross margin
ResMed Inc.'s gross margin over the twelve months to 30 June 2026 was 61.1%. Over the past ten years it has ranged from 55.8% (fiscal 2023) to 61.1% (fiscal 2026) — the current reading is the highest in ten years. That is above the Medical Instruments & Supplies industry median of 54.6% and above the Healthcare sector median of 53.7%.
Gross margin, annual
Annual
| Period | Gross margin | Change (points) |
|---|---|---|
| FY2026 | 61.1% | 1.70 |
| FY2025 | 59.4% | 2.69 |
| FY2024 | 56.7% | 0.89 |
| FY2023 | 55.8% | (0.79) |
| FY2022 | 56.6% | (0.96) |
| FY2021 | 57.5% | (0.56) |
| FY2020 | 58.1% | 0.77 |
| FY2019 | 57.3% | 0.28 |
| FY2018 | 57.0% | (1.11) |
| FY2017 | 58.2% | 0.15 |
Quarterly
| Period | Gross margin | Change (points) |
|---|---|---|
| Jun 2026 | 58.8% | (3.41) |
| Mar 2026 | 62.3% | 0.49 |
| Dec 2025 | 61.8% | 0.30 |
| Sep 2025 | 61.5% | 0.62 |
| 42 more quarters | Free account |
Against its own ten years
Low 55.8%
High 61.1%
Ten-year median
57.8%
Current reading's percentile
100
Gross margin against peers
| Company | Gross margin |
|---|---|
| COO The Cooper Companies, Inc. compare | 65.9% |
| RMD ResMed Inc. | 61.1% |
| ALC Alcon compare | 56.9% |
| SOLV Solventum Corporation compare | 54.7% |
| RGEN Repligen Corporation compare | 53.5% |
| BDX Becton, Dickinson and Company compare | 46.7% |
| MDLN Medline Inc. compare | 46.3% |
| WST West Pharmaceutical Services, Inc. compare | 36.8% |
| BAX Baxter International Inc. compare | 30.1% |
| Medical Instruments & Supplies industry median | 54.6% |
| Healthcare sector median | 53.7% |
| Market median | 46.3% |
What Gross margin is
Gross Margin tells an investor how much of each sale a company keeps after paying the direct costs of making or buying what it sells.
Gross Profit ÷ Revenue
More on RMD
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- The full statement